Polyomaviruses
Polyomavirus BK
BK polyomavirus (BKV, BKPyV) is a small, non-enveloped DNA virus belonging to the family Polyomaviridae and is widespread in the human population.

O patogenu
BK polyomavirus (BKV, BKPyV) is a small, non-enveloped DNA virus belonging to the family Polyomaviridae and is widespread in the human population. Primary infection most commonly occurs in childhood and is usually asymptomatic or mild. The virus subsequently persists lifelong in a latent form, primarily in renal tubular cells and the urothelium. In healthy individuals, periodic reactivation may occur with asymptomatic viral shedding in urine, without the development of clinical disease.
BKV is of particular clinical importance in immunocompromised patients. Following kidney transplantation, reactivation may lead to BK polyomavirus-associated nephropathy (BKVN/PyVAN), which can cause severe damage to the transplanted organ; hemorrhagic cystitis is also an important complication following hematopoietic stem cell transplantation. Serological detection of anti-BKV IgG provides information on previous exposure and the patient's immune status. Seroconversion supports evidence of primary infection, while a significant increase in IgG levels in paired samples may indicate reinfection or reactivation. Assessment of BKV serostatus before transplantation and its subsequent monitoring may contribute to evaluating the risk of infection and related complications.
VIDIA brings a unique solution for BKV serological diagnostics: ELISA-VIDITEST anti-BKV IgG enables semiquantitative determination of specific anti-BKV IgG antibodies.
Portfolio
Dostupné assays
Portfolio pro tento patogen průběžně doplňujeme. Napište nám na obchod@vidia.cz a pošleme dostupné varianty.
Časté otázky
Často kladené otázky
What is BKV and when does serological testing make sense?
BK polyomavirus (BKPyV) is a widespread non-enveloped DNA virus. Primary infection most often occurs in childhood, and the virus then persists mainly in cells of the urinary tract and kidneys. In immunocompromised patients, especially after kidney transplantation, it can reactivate and cause BK polyomavirus-associated nephropathy (BKPyVAN/BKVN), with a risk of graft damage or loss. Anti-BKV IgG serology provides information about prior contact and the humoral immune response to BKV. Its significance lies mainly in characterizing the serostatus of the donor and recipient and in assessing the immunological context. Current international recommendations emphasize that routine pre- or post-transplant BKV serology is not yet a standard tool for care management; quantitative detection of BKPyV DNA is decisive for monitoring viral replication.
How does the serological test relate to PCR monitoring of viral load after transplantation?
These methods provide different information and are not interchangeable. Anti-BKV IgG characterizes the patient's humoral response, while quantitative PCR/QNAT directly determines the amount of BKPyV DNA in plasma and allows monitoring of current viral replication. Regular monitoring of BKPyV DNAemia is therefore the standard for clinical monitoring after kidney transplantation. International consensus recommends testing plasma BKPyV DNA in kidney recipients monthly up to month 9 and then every 3 months up to 2 years after transplantation. Serology can provide supplementary information on immune status but does not replace PCR monitoring.
What does a positive anti-BKV IgG result mean in a patient before kidney transplantation?
A positive anti-BKV IgG result mainly means that the patient has had a BKV infection and developed a specific humoral immune response. Given the high seroprevalence of BKV in the adult population, this is a common finding. Positivity alone does not indicate active viral replication, BKV nephropathy, or protection against post-transplant reactivation. In terms of risk, the combination of donor and recipient status matters; for example, a seropositive donor and a seronegative recipient may represent a higher-risk combination.
What does it mean in practice that the test is semi-quantitative?
A semi-quantitative ELISA does not indicate the amount of virus or the number of BKV DNA copies. The result expresses the relative level of specific IgG antibodies relative to a calibrator or cut-off value, allowing a negative or positive result to be distinguished and relative changes in the antibody response to be tracked. A rise in anti-BKV IgG in paired samples can accompany primary infection, reinfection or reactivation, but cannot be interpreted as equivalent to viral load determined by PCR. The ELISA-VIDITEST anti-BKV IgG kit is intended precisely for qualitative/semi-quantitative determination.
What type of sample does the test require?
ELISA-VIDITEST anti-BKV IgG is validated for human serum and plasma.
How long does it take to get a result?
The kit uses an incubation protocol of 30/30/10 minutes at room temperature, that is 70 minutes of incubation. Total laboratory time is somewhat longer due to sample preparation, washing and photometric reading.
Nenašli jste, co hledáte?
Pomůžeme Vám najít vhodné diagnostické řešení
Popište nám, co potřebujete vyšetřit, a náš produktový tým Vám pomůže najít vhodné diagnostické řešení. Odpovíme Vám do 24 hodin.
Preferujete e-mail? Napište nám na obchod@vidia.cz
